Richard Scott Struthers - Dec 2, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Signature
Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Dec 2, 2024
Transactions value $
-$575,700
Form type
4
Date filed
12/4/2024, 04:30 PM
Previous filing
May 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$576K -10K -9.09% $57.57 100K Dec 2, 2024 By Family Trust 4 F1, F2
holding CRNX Common Stock 257K Dec 2, 2024 Direct
holding CRNX Common Stock 571K Dec 2, 2024 By Family Trust 1
holding CRNX Common Stock 110K Dec 2, 2024 By Family Trust 2
holding CRNX Common Stock 110K Dec 2, 2024 By Family Trust 3
holding CRNX Common Stock 1K Dec 2, 2024 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $57.57 per share. The range of sales prices on the transaction date was $56.90 to $58.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.